Insmed, Inc. (NASDAQ:INSM) Shares Bought by Skandinaviska Enskilda Banken AB publ

Key Points

• Skandinaviska Enskilda Banken AB publ increased its holdings in Insmed, Inc. by 31.8% in Q1, now owning 27,789 shares valued at approximately $2.12 million.
• A host of analysts have recently upgraded Insmed's stock, with target prices raised to as high as $115.00, leading to an average rating of "Moderate Buy" and a consensus target price of $109.20.
• Insmed experienced a 3.2% rise in stock price recently, reaching $105.00, despite reporting a loss of ($1.42) EPS in its latest earnings announcement.

Skandinaviska Enskilda Banken AB publ grew its holdings in Insmed, Inc. (NASDAQ:INSM - Free Report) by 31.8% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 27,789 shares of the biopharmaceutical company's stock after buying an additional 6,705 shares during the quarter. Skandinaviska Enskilda Banken AB publ's holdings in Insmed were worth $2,120,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Darwin Global Management Ltd. increased its position in shares of Insmed by 23.5% during the fourth quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company's stock worth $894,796,000 after purchasing an additional 2,463,261 shares in the last quarter. Norges Bank acquired a new position in Insmed during the fourth quarter worth $126,606,000. Brown Advisory Inc. acquired a new position in Insmed during the fourth quarter worth $45,773,000. Adage Capital Partners GP L.L.C. boosted its stake in Insmed by 59.6% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,647,562 shares of the biopharmaceutical company's stock worth $113,748,000 after buying an additional 615,000 shares during the last quarter. Finally, Capital International Investors boosted its stake in Insmed by 9.1% during the fourth quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company's stock worth $491,357,000 after buying an additional 593,206 shares during the last quarter.

Insmed Trading Up 0.3%

INSM traded up $0.38 during mid-day trading on Friday, hitting $107.66. 1,096,373 shares of the stock were exchanged, compared to its average volume of 2,754,447. The firm's fifty day moving average is $93.59 and its two-hundred day moving average is $80.77. Insmed, Inc. has a 1-year low of $60.40 and a 1-year high of $108.64. The company has a current ratio of 5.86, a quick ratio of 5.44 and a debt-to-equity ratio of 11.38. The company has a market cap of $20.42 billion, a PE ratio of -18.10 and a beta of 0.90.

Insmed (NASDAQ:INSM - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.36) by ($0.06). Insmed had a negative return on equity of 446.98% and a negative net margin of 265.93%. The firm had revenue of $92.82 million for the quarter, compared to analyst estimates of $91.63 million. During the same period in the previous year, the company posted ($1.06) EPS. Insmed's revenue was up 22.9% on a year-over-year basis. Equities analysts forecast that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have weighed in on INSM. Jefferies Financial Group reissued a "buy" rating on shares of Insmed in a research note on Tuesday, June 10th. Morgan Stanley boosted their price objective on Insmed from $102.00 to $108.00 and gave the stock an "overweight" rating in a research note on Thursday, July 17th. Mizuho boosted their price objective on Insmed from $96.00 to $110.00 and gave the stock an "outperform" rating in a research note on Wednesday, June 11th. Royal Bank Of Canada boosted their price objective on Insmed from $99.00 to $106.00 and gave the stock an "outperform" rating in a research note on Wednesday, June 11th. Finally, UBS Group lowered their price objective on Insmed from $110.00 to $109.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. One analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat, Insmed has a consensus rating of "Moderate Buy" and a consensus price target of $109.20.

Insider Transactions at Insmed

In related news, CEO William Lewis sold 129,805 shares of the stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $100.39, for a total transaction of $13,031,123.95. Following the transaction, the chief executive officer owned 233,924 shares of the company's stock, valued at approximately $23,483,630.36. This represents a 35.69% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Sara Bonstein sold 58,400 shares of the stock in a transaction dated Monday, July 21st. The stock was sold at an average price of $102.67, for a total value of $5,995,928.00. Following the transaction, the chief financial officer directly owned 73,505 shares in the company, valued at approximately $7,546,758.35. The trade was a 44.27% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 599,767 shares of company stock worth $54,625,108 in the last 90 days. Insiders own 3.00% of the company's stock.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.